337 related articles for article (PubMed ID: 26180199)
1. Activation of Lysophosphatidic Acid Receptor Type 1 Contributes to Pathophysiology of Spinal Cord Injury.
Santos-Nogueira E; López-Serrano C; Hernández J; Lago N; Astudillo AM; Balsinde J; Estivill-Torrús G; de Fonseca FR; Chun J; López-Vales R
J Neurosci; 2015 Jul; 35(28):10224-35. PubMed ID: 26180199
[TBL] [Abstract][Full Text] [Related]
2. Lysophosphatidic acid receptor type 2 activation contributes to secondary damage after spinal cord injury in mice.
López-Serrano C; Santos-Nogueira E; Francos-Quijorna I; Coll-Miró M; Chun J; López-Vales R
Brain Behav Immun; 2019 Feb; 76():258-267. PubMed ID: 30550929
[TBL] [Abstract][Full Text] [Related]
3. Blockage of lysophosphatidic acid signaling improves spinal cord injury outcomes.
Goldshmit Y; Matteo R; Sztal T; Ellett F; Frisca F; Moreno K; Crombie D; Lieschke GJ; Currie PD; Sabbadini RA; Pébay A
Am J Pathol; 2012 Sep; 181(3):978-92. PubMed ID: 22819724
[TBL] [Abstract][Full Text] [Related]
4. Lysophosphatidic acid propagates post-injury Schwann cell dedifferentiation through LPA
Szepanowski F; Szepanowski LP; Mausberg AK; Kleinschnitz C; Kieseier BC; Stettner M
Neurosci Lett; 2018 Jan; 662():136-141. PubMed ID: 29051083
[TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidic acid receptor
Hoshino Y; Okuno T; Saigusa D; Kano K; Yamamoto S; Shindou H; Aoki J; Uchida K; Yokomizo T; Ito N
FASEB J; 2022 Apr; 36(4):e22236. PubMed ID: 35218596
[TBL] [Abstract][Full Text] [Related]
6. Interfering with lysophosphatidic acid receptor edg2/lpa
Gento-Caro Á; Vilches-Herrando E; García-Morales V; Portillo F; Rodríguez-Bey G; González-Forero D; Moreno-López B
Neuropathol Appl Neurobiol; 2021 Dec; 47(7):1004-1018. PubMed ID: 33508894
[TBL] [Abstract][Full Text] [Related]
7. Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain.
Ma L; Uchida H; Nagai J; Inoue M; Chun J; Aoki J; Ueda H
Mol Pain; 2009 Nov; 5():64. PubMed ID: 19912636
[TBL] [Abstract][Full Text] [Related]
8. Lysophosphatidic acid and its receptors LPA1 and LPA3 mediate paclitaxel-induced neuropathic pain in mice.
Uchida H; Nagai J; Ueda H
Mol Pain; 2014 Nov; 10():71. PubMed ID: 25411045
[TBL] [Abstract][Full Text] [Related]
9. Anatomical location of LPA1 activation and LPA phospholipid precursors in rodent and human brain.
González de San Román E; Manuel I; Giralt MT; Chun J; Estivill-Torrús G; Rodríguez de Fonseca F; Santín LJ; Ferrer I; Rodríguez-Puertas R
J Neurochem; 2015 Aug; 134(3):471-85. PubMed ID: 25857358
[TBL] [Abstract][Full Text] [Related]
10. Autotaxin and lysophosphatidic acid1 receptor-mediated demyelination of dorsal root fibers by sciatic nerve injury and intrathecal lysophosphatidylcholine.
Nagai J; Uchida H; Matsushita Y; Yano R; Ueda M; Niwa M; Aoki J; Chun J; Ueda H
Mol Pain; 2010 Nov; 6():78. PubMed ID: 21062487
[TBL] [Abstract][Full Text] [Related]
11. Lysophosphatidic acid and its receptor LPA
Srikanth M; Chew WS; Hind T; Lim SM; Hay NWJ; Lee JHM; Rivera R; Chun J; Ong WY; Herr DR
Eur J Pharmacol; 2018 Dec; 841():49-56. PubMed ID: 30321532
[TBL] [Abstract][Full Text] [Related]
12. Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure.
Panchatcharam M; Miriyala S; Yang F; Rojas M; End C; Vallant C; Dong A; Lynch K; Chun J; Morris AJ; Smyth SS
Circ Res; 2008 Sep; 103(6):662-70. PubMed ID: 18703779
[TBL] [Abstract][Full Text] [Related]
13. Altered cleavage plane orientation with increased genomic aneuploidy produced by receptor-mediated lysophosphatidic acid (LPA) signaling in mouse cerebral cortical neural progenitor cells.
McDonald WS; Miyamoto K; Rivera R; Kennedy G; Almeida BSV; Kingsbury MA; Chun J
Mol Brain; 2020 Dec; 13(1):169. PubMed ID: 33317583
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis.
Poon MM; Lorrain KI; Stebbins KJ; Edu GC; Broadhead AR; Lorenzana AO; Paulson BE; Baccei CS; Roppe JR; Schrader TO; Valdez LJ; Xiong Y; Chen AC; Lorrain DS
Sci Rep; 2024 May; 14(1):10573. PubMed ID: 38719983
[TBL] [Abstract][Full Text] [Related]
15. Lysophosphatidic acid as the initiator of neuropathic pain.
Ueda H
Biol Pharm Bull; 2011; 34(8):1154-8. PubMed ID: 21804198
[TBL] [Abstract][Full Text] [Related]
16. Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass.
Gennero I; Laurencin-Dalicieux S; Conte-Auriol F; Briand-Mésange F; Laurencin D; Rue J; Beton N; Malet N; Mus M; Tokumura A; Bourin P; Vico L; Brunel G; Oreffo RO; Chun J; Salles JP
Bone; 2011 Sep; 49(3):395-403. PubMed ID: 21569876
[TBL] [Abstract][Full Text] [Related]
17. Role of lysophosphatidic acid receptor LPA2 in the development of allergic airway inflammation in a murine model of asthma.
Zhao Y; Tong J; He D; Pendyala S; Evgeny B; Chun J; Sperling AI; Natarajan V
Respir Res; 2009 Nov; 10(1):114. PubMed ID: 19930563
[TBL] [Abstract][Full Text] [Related]
18. Involvement of lysophosphatidic acid-induced astrocyte activation underlying the maintenance of partial sciatic nerve injury-induced neuropathic pain.
Ueda H; Neyama H; Nagai J; Matsushita Y; Tsukahara T; Tsukahara R
Pain; 2018 Nov; 159(11):2170-2178. PubMed ID: 29939962
[TBL] [Abstract][Full Text] [Related]
19. Differential anatomical and cellular expression of lysophosphatidic acid receptor 1 in adult mouse brain.
Kajitani N; Okada-Tsuchioka M; Kano K; Omori W; Boku S; Aoki J; Takebayashi M
Biochem Biophys Res Commun; 2020 Oct; 531(2):89-95. PubMed ID: 32718668
[TBL] [Abstract][Full Text] [Related]
20. Lysophosphatidic acid receptors (LPARs): Potential targets for the treatment of neuropathic pain.
Velasco M; O'Sullivan C; Sheridan GK
Neuropharmacology; 2017 Feb; 113(Pt B):608-617. PubMed ID: 27059127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
